270 related articles for article (PubMed ID: 10910015)
1. Clinical efficacy of reboxetine in major depression.
Schatzberg AF
J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
[TBL] [Abstract][Full Text] [Related]
2. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
3. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
Hajós M; Fleishaker JC; Filipiak-Reisner JK; Brown MT; Wong EH
CNS Drug Rev; 2004; 10(1):23-44. PubMed ID: 14978512
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
5. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
[TBL] [Abstract][Full Text] [Related]
6. Chairman's overview. The place of reboxetine in antidepressant therapy.
Montgomery SA
J Clin Psychiatry; 1998; 59 Suppl 14():26-9. PubMed ID: 9818628
[TBL] [Abstract][Full Text] [Related]
7. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
8. The role of norepinephrine in the treatment of depression.
J Clin Psychiatry; 1999 Sep; 60(9):623-31. PubMed ID: 10520985
[No Abstract] [Full Text] [Related]
9. Predicting response: noradrenaline reuptake inhibition.
Montgomery SA
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
[TBL] [Abstract][Full Text] [Related]
10. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
11. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
Scates AC; Doraiswamy PM
Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
[TBL] [Abstract][Full Text] [Related]
12. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
[TBL] [Abstract][Full Text] [Related]
13. The effects of antidepressants on psychomotor function with particular reference to reboxetine.
Hindmarch I
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S17-21; discussion S71-3. PubMed ID: 9169307
[TBL] [Abstract][Full Text] [Related]
14. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.
Brunello N; Mendlewicz J; Kasper S; Leonard B; Montgomery S; Nelson J; Paykel E; Versiani M; Racagni G
Eur Neuropsychopharmacol; 2002 Oct; 12(5):461-75. PubMed ID: 12208564
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for a pure noradrenergic drug in the treatment of depression?
Montgomery SA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
[TBL] [Abstract][Full Text] [Related]
16. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
[TBL] [Abstract][Full Text] [Related]
17. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
Nelson JC; Portera L; Leon AC
Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
Dannon PN; Iancu I; Grunhaus L
Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
[TBL] [Abstract][Full Text] [Related]
19. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Papakostas GI; Nelson JC; Kasper S; Möller HJ
Eur Neuropsychopharmacol; 2008 Feb; 18(2):122-7. PubMed ID: 17719752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
